Simcere Pharmaceutical Group Limited (HK:2096) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Simcere Pharmaceutical Group Limited anticipates a revenue drop for the first half of 2024, with a projected 7.0% to 8.8% decrease compared to the previous year, primarily due to reduced promotion service revenue and changes in the COVID-19 situation affecting drug sales. Profits for the company are also expected to fall significantly by approximately 78.6% to 81.2%, largely influenced by a change in fair value of investments and the lack of one-off gains from subsidiary disposals that were present last year. These preliminary figures are based on unaudited accounts and subject to final adjustments with complete interim results to be released in late August 2024.
For further insights into HK:2096 stock, check out TipRanks’ Stock Analysis page.